The European future of Wyeth’s depression treatment Ellefore has been thrown into doubt after the pharma company withdrew its application …
GlaxoSmithKline has extended its reach into emerging markets by acquiring Bristol-Myers Squibb’s Egyptian mature products business for £125 millionThe move …
Contract research organisations are now play a key role in the development of most of the industry's drugs, with some …
NICE has spurned GSK's risk-sharing proposal for its breast cancer treatment Tyverb, saying the drug is still too expensive to …
Oxford BioMedica has settled on a permanent chief executive, promoting John Dawson from his acting leadership position. Chairman professor Alan …

A collective of European legislators, patient groups and the pharma industry have reiterated the call for Europe’s ban on pharma …
Johnson & Johnson has named a new chairman for its struggling pharmaceuticals group, and kept the role under female leadership. …
How did you get into your current role After completing my D.Phil at Oxford, I looked for an opportunity in …
Battle for HIV drug market share getting fiercerThe HIV market, worth $9.3 billion in 2007, is expected to grow to …
AstraZeneca's head of global drug discovery Jan Lundberg says his younger years as a sportsman have made him a determined …
Novartis says new data on Glivec shows it has potential to treat a life-threatening heart condition, despite failing to meet …
A new report from the World Health Organisation says England's mental health care has undergone a 'transformation' in the last …
British pharma is free to provide necessary and sufficient information to patients about its drugs, and an example to be …
Lilly is to buy ImClone for $6.5 billion after outbidding Bristol-Myers Squibb for the biotech company. Lilly says the acquisition …
Roche is to develop a potential cancer therapy with two business partners. Genentech, the Swiss biotech company GlycArt – wholly-owned …
A new advertising agency has been launched as the UK’s first ‘virtual’ healthcare outfit, and aims to undercut traditional agencies …
Is an Rx-to-OTC move the right prescription to protect pharma revenues and cut healthcare costs? The growing cost of developing …